Uncategorized

$OMER update

Omeros has rebounded in the past few months and is currently at $5.41. The rise is due to the approval of preconditions for OMS302. This stock fluctuates with market approval and drug testing but I recommend holding this stock.

$MO update

Altria is at $36.27. This stock maintains a high divident payer and has consistent earnings. Cigarette volumes still tend to be flat but smokeless tobacco and wine volumes continue to increase. This stock is steady and I recommend the Club hold.

$OMER update

In recent news, OMER presented at the 2013 Future Leaders in Biotech Industry in 04/2013. This stock has dropped below $4.00 this month. This stock is looking less like an opportunity. Important drugs are awaiting FDA approval, but I am not seeing enough supporting data that, even with new approvals, we will see a market …

$OMER update Read More »

$MO

Altria’s current share price is $35.48, close to it’s 52 week high of $36.29. Altria has outperformed the S&P by 60%. This company continues to show a strong balance sheet. As this company shares a major portion of its profits to shareholders and continues to diversify in new markets (smokeless products, cigars, wines etc.) I …

$MO Read More »

$OMER update

Althought this stock has fallen recently, I still contend it is a undervalued biotech stock. This stock fluctuates with the news of its drug trials. Most recently, its leading drug candidate OMS302 has had a successful phase III trial and no safety concerns were identified. If this drug is approved, sales could reach $600 million …

$OMER update Read More »

$MO update

Altria recently declared a regular quarterly divident of $0.44 per share, payable on 4/10/13 (Ex date is 03/13/13). As always, MO is susceptible to federal, state, and USDA regulation, and litigation but I am confident in its 2013 guidance. They have shown success in responding to consumer preferences and developing new products and markets.

$OMER

Omeros, clinical stage biopharmaceutical company, announced on 10/3, the completion of enrollment in OMS302 phase 3 clinical trial. OMS302  is one of Omero’s proprietary PharmocoSurgery products. There has been a gain since last meeting, with a stock price of $10.80, up from around $9.00 last month. With only positive news and the the stock still …

$OMER Read More »

$MO

Altria group Inc, manufacturer of cigarettes, smokeless products, and wine in the US, is a P/E of 15.7 , below the average tobacco industry PE. Share are up 14.7%  year do date and all analysts rate it a hold. The next dividend payment date for MO is 10/10/2012. Press since the last meeting include “Altria …

$MO Read More »